FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365483670> ?p ?o ?g. }

• W4365483670 abstract "Cystic fibrosis (CF) is a life-limiting genetic condition affecting various organ systems including the gastrointestinal tract, endocrine system and especially the respiratory tract. Pulmonary exacerbations in CF result in increased symptoms, an acceleration in the rate of lung decline and an increased need for treatment. Early detection of infections or clinical worsening provides an opportunity for proactive treatment that may affect clinical outcomes.To evaluate whether digital technology can effectively predict pulmonary exacerbations to allow earlier intervention and improved health outcomes without increasing the burden of treatment in people with CF.We used standard, extensive Cochrane search methods. We searched the Cochrane Cystic Fibrosis Trials Register and the reference lists of relevant articles and reviews on 13 October 2022. We searched Embase and the clinical trial registries on 3 January 2023.We included randomised controlled trials (RCTs) or quasi-RCTs in people with CF looking at whether digital technology can effectively predict pulmonary exacerbations to allow earlier intervention and improved health outcomes without increasing the burden of treatment. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods. Our primary outcomes were 1. pulmonary exacerbations and 2. quality of life (QoL). Our secondary outcomes were 3. lung function, 4. hospitalisations, 5. intravenous (IV) antibiotics, 6. microbiology, 7. cost-effectiveness and 8.We used GRADE to assess certainty of evidence.We included three studies (415 participants) in people with CF aged 15 to 41 years over a 12-month period. One was a multicentre RCT, whilst two were single-centre RCTs. The three studies were mostly similar in their risk of bias, having low or unclear risk of selection bias but a high risk of detection bias, due to the unblinded design of these studies. The studies used a variety of digital technologies to monitor symptoms such as a digital symptom diary either with or without home spirometry monitoring. As the trials only included adults and older children, we are not certain that the results would apply to younger children. One of our primary outcomes was to assess time to detection of pulmonary exacerbation and number of pulmonary exacerbations identified between the intervention and routine care groups. We were largely unable to pool results in a meta-analysis due to the variety of methodologies and ways of reporting data. Two studies noted a shorter time to detection of exacerbations in the intervention group and one of these also reported that the intervention group had a shorter time to first exacerbation (hazard ratio for time to first exacerbation 1.45, 95% confidence interval (CI) 1.09 to 1.93), whilst a further study reported a shorter time to detection of exacerbations in the intervention group requiring oral or IV antibiotics compared to the control group (median: 70 (interquartile range (IQR) 123) days with intervention versus 141 (IQR 140) days with control; P = 0.02). However, all three studies were concordant in finding no probable effect on spirometry in the intervention groups when compared with their routine care groups over a 12-month period. We found that there is probably no difference between groups with regard to QoL scores across most domains except for Weight and Body Image, which favoured the usual care group. There is also probably no difference in the number of days of additional IV antibiotics needed or newly detected pathogens. No studies reported serious adverse events directly linked to the intervention and one study reported their smartphone application was generally well received.Pulmonary exacerbations are universally accepted to be detrimental to progression of CF-related lung disease, therefore, it is intuitive that early detection and intervention would help to improve outcomes. Digital technology provides an opportunity to detect physiological and symptomatic changes to identify exacerbations early. Our review found that digital technologies based on recording physiological change (spirometry) and symptoms probably allow earlier identification of exacerbations as a group. However, this may not reduce the number of exacerbations warranting IV antibiotics and there is probably no effect on lung function. This may be partly due to inconsistent definitions of pulmonary exacerbations and discrepancy in the management strategies for pulmonary exacerbations. Overall, the intervention may make little or no difference to QoL scores. The adherence to and uptake of digital technologies, especially those which include physiological measurements, are not well sustained and the costs of these need to be balanced against the clinical efficacy." @default.
• W4365483670 created "2023-04-15" @default.
• W4365483670 creator A5000146703 @default.
• W4365483670 creator A5071649721 @default.
• W4365483670 creator A5086214086 @default.
• W4365483670 date "2023-04-14" @default.
• W4365483670 modified "2023-09-26" @default.
• W4365483670 title "Digital technology for early identification of exacerbations in people with cystic fibrosis" @default.
• W4365483670 cites W1555576985 @default.
• W4365483670 cites W1608442163 @default.
• W4365483670 cites W1969833938 @default.
• W4365483670 cites W1980977136 @default.
• W4365483670 cites W1987707183 @default.
• W4365483670 cites W2029582025 @default.
• W4365483670 cites W2032406037 @default.
• W4365483670 cites W2070319783 @default.
• W4365483670 cites W2081694712 @default.
• W4365483670 cites W2083481549 @default.
• W4365483670 cites W2125435699 @default.
• W4365483670 cites W2125504898 @default.
• W4365483670 cites W2130235475 @default.
• W4365483670 cites W2142930532 @default.
• W4365483670 cites W2151174404 @default.
• W4365483670 cites W2157195518 @default.
• W4365483670 cites W2161450374 @default.
• W4365483670 cites W2178374533 @default.
• W4365483670 cites W2410280536 @default.
• W4365483670 cites W2415989921 @default.
• W4365483670 cites W2443044759 @default.
• W4365483670 cites W2496887625 @default.
• W4365483670 cites W2580119701 @default.
• W4365483670 cites W2588463362 @default.
• W4365483670 cites W2599873526 @default.
• W4365483670 cites W2620705521 @default.
• W4365483670 cites W2620934327 @default.
• W4365483670 cites W2621261528 @default.
• W4365483670 cites W2625491143 @default.
• W4365483670 cites W2782476820 @default.
• W4365483670 cites W2800681577 @default.
• W4365483670 cites W2802851561 @default.
• W4365483670 cites W2803875202 @default.
• W4365483670 cites W2805098667 @default.
• W4365483670 cites W2899639745 @default.
• W4365483670 cites W2919362756 @default.
• W4365483670 cites W2921653623 @default.
• W4365483670 cites W2941764236 @default.
• W4365483670 cites W2954302347 @default.
• W4365483670 cites W2961143390 @default.
• W4365483670 cites W2972789169 @default.
• W4365483670 cites W2982573304 @default.
• W4365483670 cites W3033604970 @default.
• W4365483670 cites W3044591319 @default.
• W4365483670 cites W3094818214 @default.
• W4365483670 cites W3120155305 @default.
• W4365483670 cites W3138006446 @default.
• W4365483670 cites W3138182042 @default.
• W4365483670 cites W3154957249 @default.
• W4365483670 cites W3174704253 @default.
• W4365483670 cites W3198550711 @default.
• W4365483670 cites W3199996149 @default.
• W4365483670 cites W3201773783 @default.
• W4365483670 cites W3206154674 @default.
• W4365483670 cites W3207314269 @default.
• W4365483670 cites W4200367629 @default.
• W4365483670 cites W4211056322 @default.
• W4365483670 cites W4214721068 @default.
• W4365483670 cites W4220691101 @default.
• W4365483670 cites W4225794127 @default.
• W4365483670 cites W4281721868 @default.
• W4365483670 cites W4281770056 @default.
• W4365483670 cites W4283786067 @default.
• W4365483670 cites W4365483670 @default.
• W4365483670 doi "https://doi.org/10.1002/14651858.cd014606.pub2" @default.
• W4365483670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37057835" @default.
• W4365483670 hasPublicationYear "2023" @default.
• W4365483670 type Work @default.
• W4365483670 citedByCount "1" @default.
• W4365483670 countsByYear W43654836702023 @default.
• W4365483670 crossrefType "journal-article" @default.
• W4365483670 hasAuthorship W4365483670A5000146703 @default.
• W4365483670 hasAuthorship W4365483670A5071649721 @default.
• W4365483670 hasAuthorship W4365483670A5086214086 @default.
• W4365483670 hasConcept C126322002 @default.
• W4365483670 hasConcept C159110408 @default.
• W4365483670 hasConcept C168563851 @default.
• W4365483670 hasConcept C17744445 @default.
• W4365483670 hasConcept C177713679 @default.
• W4365483670 hasConcept C1862650 @default.
• W4365483670 hasConcept C187212893 @default.
• W4365483670 hasConcept C189708586 @default.
• W4365483670 hasConcept C199539241 @default.
• W4365483670 hasConcept C2776478404 @default.
• W4365483670 hasConcept C2776938444 @default.
• W4365483670 hasConcept C2779473830 @default.
• W4365483670 hasConcept C2779951463 @default.
• W4365483670 hasConcept C535046627 @default.
• W4365483670 hasConcept C71924100 @default.
• W4365483670 hasConcept C95190672 @default.
• W4365483670 hasConceptScore W4365483670C126322002 @default.
• W4365483670 hasConceptScore W4365483670C159110408 @default.

• next